Mineralocorticoid receptor modulators: A patent review (2007-2012)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 2, 2014, Pages 177-183

  Collin, Matthieu ^a   Niemann, Frederic ^b   Jaisser, Frédéric ^c,d  

^a INSERM   (France)

^b Cabinet Plasseraud   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d CHU NANCY BRABOIS   (France)

Author keywords

Aldosterone; Mineralocorticoid receptor

Indexed keywords

BAY 948862; MINERALOCORTICOID ANTAGONIST; UNCLASSIFIED DRUG;

DRUG MANUFACTURE; HUMAN; PATENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892723636     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.854772     Document Type: Review

References (60)

1. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001;280(2):F181-92
2. Bienvenu LA, Reichelt ME, Delbridge LM, Young MJ. Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte. Clin Sci (Lond) 2013;125(9):409-21
3. Perrier R, Richard S, Sainte-Marie Y, et al. A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol 2005;569(Pt 1):153-62
4. Gomez AM, Rueda A, Sainte-Marie Y, et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009;119(16):2179-87
5. Messaoudi S, Gravez B, Tarjus A, et al. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension 2013;61(2):361-7
6. Simpson SA, Tait JF. The nature of the circulating hormones of the adrenal cortex in man. Arch Middx Hosp 1953;3(4):209-18
7. Funder JW, Funder JW, Pearce PT, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242(4878):583-5
8. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237(4812):268-75 .. Molecular identification of MR coding sequence allowing the identification of the extended expression pattern of MR.
9. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007;5:e012
10. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011;79(10):1051-60
11. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 2012;21(2):147-56
12. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2011;350(2):256-65
13. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992;120(6):893-901 .. Landmark study showing extrarenal effects of mineralocorticoid on cardiac extracellular matrix remodeling independent of blood pressure increase.
14. Beygui F, Labbé JP, Cayla G, et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol 2011;167(1):73-9
15. McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012;18(9):1429-33
16. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010;12(4):252-7
17. Rossi GP, Sechi LA, Giacchetti G, et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008;19(3):88-90
18. Sainte Marie Y, Toulon A, Paus R, et al. Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am J Pathol 2007;171(3):846-60
19. Zhao M, Bousquet E, Valamanesh F, et al. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci 2011;52(9):6340-7
20. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122(7):2672-9 .. Repositioning of eplerenone showing impressive benefit in patients with a vision-threatening eye disease.
21. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J 2010;24(9):3405-15
22. DeRijk RH, de Kloet ER, Zitman FG, van Leeuwen N. Mineralocorticoid receptor gene variants as determinants of HPA axis regulation and behavior. Endocr Dev 2011;20:137-48
23. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012;81(10):955-68
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17
25. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-21
26. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21
27. Bayer Healthcare Ag. 4-chromenonyl-1,4-dihydropyridines and their use. WO2007025604; 2007
28. Bayer Healthcare Ag. Substituted 4-aryl-1,4-dihydro-1,6- naphthyridinamides and use thereof. US 8436180 B2; 2008
29. Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010;285(39):29932-40
30. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem 2012;7(8):1385-403
31. Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012;14(6):668-75
32. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34(31):2453-63 .. First clinical trial demonstrating efficacy between BAY 94-8862 in patients with chonic kidney disease with better safety profile than spironolactone.
33. Boehringer Ingelheim, Int. Pyridyl ureas as mineralocorticoid receptor antagonists. WO2012064631; 2012
34. Daiichi Sankyo Co Ltd. Pharmaceutical preparation containing mineralcorticoid receptor antagonist. WO2010098286; 2010
35. Daiichi Sankyo Co Ltd. Atropisomer of pyrrole derivative. WO2008126831; 2008
36. Available from: http://www.exelixis.com/ pipeline/xl550
37. Dainippon Sumitomo Pharma Co. Biaryl amide derivative or pharmaceutically acceptable salt thereof. WO2012008435; 2012
38. Nariai T, Fujita K, Mori M, et al. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. J Pharmacol Sci 2011;115(3):346-53
39. Eli Lilly Co. Mineralocorticoid receptor antagonist and methods of use. WO2010104721; 2010
40. Eli Lilly Co. 6H-Dibenz0 [B, E] Oxepine derived nonsteroidal mineralocorticoid receptor antagonists. WO200985584; 2009
41. Merck & Co, Inc. Mineralocorticoid receptor modulators. WO200978934; 2009
42. Merck & Co, Inc. Mineralocorticoid receptor modulators. WO2008118319; 2008
43. Mitsubishi Tanabe Pharma Corp. Fused bicyclic compound. WO2009017190; 2009
44. Tanabe Seiyaku Co. Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents. WO2007089034; 2007
45. Available from: http://clinicaltrials.gov/ ct2/show/NCT01427972? term=LY2623091&rank=1
46. Pfizer. Pyrazoline compounds as mineralocorticoid receptor antagonists. WO200853300; 2008
47. Pfizer. 4,5-Dihydro-LH-Pyrazole Compounds And Their Pharmaceutical Uses. WO2010116282; 2010
48. Pfizer. Morpholine compounds as mineralocorticoid receptor antagonists. WO2011141848; 2011
49. Arhancet G.B, Woodard SS, Iyanar K, et al. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J Med Chem 2010;53(16):5970-8
50. Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo [g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010;53(16):5979-6002
51. Takeda Pharmaceutical. Fused heterocyclic compound and use thereof, T. Pharmaceutical. WO2007077961; 2007
52. Hasui T, Matsunaga N, Ora T, et al. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. J Med Chem 2011;54(24):8616-31
53. Bender S.B, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 2013;62(2):313-19
54. Lastra G, Dhuper S, Johnson MS, Sowers JR. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol 2010;7(10):577-84
55. Methods And Compositions For The Treatment Of Fluid Accumulation In And/Or Under The Retina, INSERM 2011
56. Farman N, Maubec E, Poeggeler B, et al. The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon? Exp Dermatol 2010;19(2):100-7
57. INSERM (Institut National de la Sante et de la Recherche Médicale). Methods and compositions for stimulating reepithelialisation during wound healing. WO2011141456; 2011
58. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012;350(2):310-17
59. Piotrowski DW. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 2012;55(18):7957-66
60. Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J 2013;34(31):2426-8